ArticleCancer immunology, immunotherapy : CII2013
Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
Article in Cancer immunology, immunotherapy : CII, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML.Frontiers in immunology · 2026Article
- Harnessing Dendritic Cell Function in Hepatocellular Carcinoma: Advances in Immunotherapy and Therapeutic Strategies.Vaccines · 2025Review
- The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes.The Journal of experimental medicine · 2024Review
- The immunomodulatory role of all-trans retinoic acid in tumor microenvironment.Clinical and experimental medicine · 2023Review
- Retinoic Acid Signaling Is Required for Dendritic Cell Maturation and the Induction of T Cell Immunity.ImmunoHorizons · 2023Article
- Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation.Cancers · 2023Review
- Impaired function of dendritic cells within the tumor microenvironment.Frontiers in immunology · 2023Review
- Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance.Frontiers in medicine · 2022Review
- Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts.Journal of pediatric surgery · 2021Article
- Emerging strategies for treating metastasis.Nature cancer · 2021Article
- Short-Chain Fatty Acids Calibrate RARα Activity Regulating Food Sensitization.Frontiers in immunology · 2021Article
- The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review.Annals of translational medicine · 2020Review
- Bacterial Quorum Sensing Molecules Promote Allergic Airway Inflammation by Activating the Retinoic Acid Response.iScience · 2020Article
- Review
- Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands.Cancer immunology, immunotherapy : CII · 2018Review
- Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10.Frontiers in immunology · 2018Review
- Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8Immunology · 2017Article
- Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Frontiers in immunology · 2017Review
- Anti-PD-1 inhibits Foxp3Cancer immunology, immunotherapy : CII · 2016Article
- Innate Lymphoid Cells in Tumor Immunity.Biomedicines · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system has evolved regulatory mechanisms to control immune responses to self-antigens. Regulatory T (Treg) cells play a pivotal role in maintaining immune tolerance, but tumour growth is associated with local immunosuppression, which can subvert effector immune responses. Indeed, the induction and recruitment of Treg cells by tumours is a major barrier in the development of effective immunotherapeutics and vaccines against cancer. Retinoic acid (RA) has been shown to promote conversion of naïve T cells into Treg cells. This study addresses the hypothesis that blocking RA receptor alpha (RARα) may enhance the efficacy of a tumour vaccine by inhibiting the induction of Treg cells. We found that RA significantly enhanced TGF-β-induced expression of Foxp3 on naïve and committed T cells in vitro and that this was blocked by an antagonist of RARα (RARi). In addition, RARi significantly suppressed TGF-β and IL-10 and enhanced IL-12 production by dendritic cells (DC) in response to killed tumour cells or TLR agonists. Furthermore, RARi augmented the efficacy of an antigen-pulsed and TLR-activated DC vaccine, significantly attenuating growth of B16 tumours in vivo and enhancing survival of mice. This protective effect was associated with significant reduction in tumour-infiltrating FoxP3(+) and IL-10(+) Treg cells and a corresponding increase in tumour-infiltrating CD4(+) and CD8(+) T cells that secreted IFN-γ. Our findings demonstrate that RARα is an important target for the development of effective anti-tumour immunotherapeutics and for improving the efficacy of cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.